Search results | antibody

Reports

Cancer Monoclonal Antibody Partnering Terms and Agreements

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Antibody Partnering Terms & Agreements

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Diagnostic Imaging Partnering Terms and Agreements

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

Antibiotics Partnering Terms and Agreements

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value   The Antibiotics Partnering Terms and more »

Gene Therapy Partnering Terms and Agreements

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Monoclonal Antibodies Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals.

Insights

Morphosys: Clear leaders in antibody generation

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications.

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Antibody

An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by …..

Seattle and Genentech expand antibody-drug conjugate collaboration

Seattle Genetics and Genentech have expanded their existing antibody-drug conjugate collaboration, in order to deliver additional preclinical ADC compounds.

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.

Current Agreements Deal Analysis Update : November 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.

Pharmacyclics: The talk of the partnering town

Pharmacyclics is a biopharmaceutical company founded in April 1991 discovering and developing medications to treat and alleviate the suffering of oncology patients.

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

Celgene and Zymeworks partner for bi-specific antibody therapeutics

Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform

Sanofi and Boehringer Ingelheim in antibody manufacturing pact

Boehringer Ingelheim and Sanofi enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies

Amgen and MD Anderson in bispecific T cell engager (BiTE) antibody pact

Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen’s bispecific T cell engager (BiTE) antibody constructs

Mersana expands fleximer antibody-drug conjugates pact with Takeda

Mersana Therapeutics have expanded their ongoing collaboration with Takeda Pharmaceutical to create novel Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets

Licensing agreement for antibody and vaccine for obesity

Sorrento Therapeutics has entered into an antibody and vaccine development collaboration with The Scripps Research Institute.

Collaboration agreement for anti-IL-16 antibody in inflammatory diseases and ischaemic reperfusion injury

London, UK, 10 October 2013: MRC Technology, a technology transfer organisation, announced today it is collaborating with Boston University to develop an anti-IL-16 antibody for use in treatment of inflammatory diseases and Ischaemic Reperfusion Injury (IRI). The project is funded in part through a Biomedical Catalyst award of £577,000, granted to MRC Technology in 2012.

Celgene big biotech deals Adimab for antibody discovery collaboration

Adimab announced a multi-target discovery biotech deals collaboration with Celgene Corporation.

Bayer Healthcare pharma partners Compugen for antibody-based therapeutics in oncology

Bayer Healthcare, a big pharma company, pharma partners Compugen in a deal for antibody-based therapeutics in oncology.

GSK and Adimab enters biotech licensing with antibody platform

Adimab announced its first platform technology transfer and biotech licensing agreement with GlaxoSmithKline, a big pharma company

Merck big pharma deals Xencor for monoclonal antibody licensing agreement

Xencor enters pharma deals with Merck for the licensing of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody to the big pharma company.